Tuberculous meningitis in patients with concurrent tuberculosis and HIV infection who have started antiretroviral therapy: the specific course and prognosis
https://doi.org/10.21292/2075-1230-2019-97-9-5-10
Abstract
The objective: to study the course of tuberculous meningitis (TM) in patients with HIV infection after the initiation of antiretroviral therapy (ART) and evaluate their effect on the outcome prognosis.
Subjects and methods. 58 patients with concurrent tuberculosis and HIV infection were examined, in whom, after initiation of ART, TM exacerbated or developed. The mean age made 36.0 ± 1.4 years; there were 45 men (77.6%). The following groups were identified: 25 patients who were admitted with diagnosis of TM and started treatment; and after ART initiation, they experienced a worsening of meningitis course of (Group I); 17 patients who received anti-tuberculosis drugs for tuberculosis in other sites and in whom, after ART initiation, the course of tuberculosis worsened and TM developed (Group II); 16 patients who started ART at the pre-hospital stage without a previously diagnosed tuberculosis, in whom TM was one of the first manifestations of active tuberculosis (Group III).
Results. Exacerbation of previously treated TM occurred in the period from 3 to 62 days (median 13.0), which was considered as a manifestation of the immune system restoration syndrome. In 20 (80.0%) patients, stabilization was achieved in the period from 30 to 278 days (median 120.0), 4 (16.0%) people died due to progression of meningitis. TM, which began for the first time after ART in patients who had taken 12 to 150 (median 40.5) doses of anti-TB drugs, developed within 5 to 90 days (median 24) and was associated with high mortality (76.5%), which could be due to drug resistance. Of the 16 patients in whom TM developed after the start of ART on an outpatient basis, active tuberculosis could not be excluded in 12 (75.0%) of them before starting treatment. Symptoms of meningitis appeared in 4-63 days (median 28.5), mortality reached 87.5%, one of the reasons could be drug resistance.
About the Authors
E V. Korzh
M. Gorky Donetsky National Medical University
Ukraine
Doctor of Medical Sciences, Professor
Ukraine
Doctor of Medical Sciences, Professor
N. A. Podchos
Republican Clinical Tuberculosis Hospital
Ukraine
Head of Tuberculosis Lung Department no. 1 for Adults
Ukraine
Head of Tuberculosis Lung Department no. 1 for Adults
References
1. Korzh E.V., Tlustova T.V. Impact of antiretroviral therapy on tuberculosis encephalomeningitis in HIV infected patients. Probl. Zdorovya i Ekologii, 2014, vol. 39, no. 1, pp. 63-67. (In Russ.)
2. Lyakh Yu.E., Guryanov V.G., Khomenko V.N., Panchenko O.А. Osnovy kompyuternoy biostatistiki. Аnaliz informatsii v biologii, meditsine i farmatsii statisticheskim paketom MedStat. [Basics of computer biostatistics. Data analysis in biology, medicine and pharmacy by MedStat software]. Donetsk, 2006, 214 p.
3. Lawn Stephen D., Robin Wood. Poor prognosis of HIV-associated tuberculous meningitis regardless of the timing of antiretroviral therapy. Clin. Infect. Dis., 2011, vol. 52, is. 11, pp. 1384-1387.
4. Marais S., Thwaites G., Schoeman J.F., Török M.E., Misra U.K., Prasad K., Donald P.R., Wilkinson R.J., Marais B.J. Tuberculous meningitis: a uniform case definition for use in clinical research. Lancet Infect. Dis., 2010, vol. 10, is. 11, pp. 803-812. doi: 10.1016/S1473-3099(10)70138-9.
5. Naomi F. Walker, Cari Stek, Sean Wasserman, Robert J. Wilkinson, Graeme Meintjes. The tuberculosis-associated immune reconstitution inflammatory syndrome: recent advances in clinical and pathogenesis research. Curr. Opin. HIV AIDS, 2018, vol. 13, is. 6, pp. 512-521. doi: 10.1097/COH.0000000000000502.
6. Rani D., Anupurbha S., Gupta M., Kumari S., Singh A. Correlation of GeneXpert and cerebrospinal fluid culture in patients of tubercular meningitis. Asian. Pac. J. Health Sci., 2018, vol. 5, is. 2, pp. 148-151. doi: 10.21276/apjhs.2018.5.2.28.
7. Ruslami R., Ganiem A. R., Dian S., Apriani L., Achmad T.H., van der Ven A.J., Borm G., Aarnoutse R.E, van Crevel R. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect. Dis., 2013, vol. 13, is. 1, pp. 27-35. doi: 10.1016/S1473-3099(12)70264-5.
8. Susan Swindells. New and noteworthy in tuberculosis diagnostics and treatment. Top Antivir. Med., 2018, vol. 26, is. 2, pp. 58-61.
9. Suzaan Marais, Graeme Meintjes, Dominique J. Pepper, Lori E. Dodd, Charlotte Schutz, Zahiera Ismail, Katalin A. Wilkinson, Robert J. Wilkinson. Frequency, severity, and prediction of tuberculous meningitis immune reconstitution inflammatory syndrome. Clin. Infect. Dis., 2013, vol. 56, is. 3, pp. 450-460. doi: 10.1093/cid/cis899.
10. Tariq Z.Al. Clinical, biochemical and immunological profiles of HIV patients developing immune reconstitution inflammatory syndrome (IRIS). Medbiotech. J., 2018, vol. 2, is. 1, pp. 124-131. doi: 10.22034/mbt.2018.61528.
11. Upasna Agarwal, Amitabh Kumar, Digamber Behera, Martyn A. French, Patricia Price. Tuberculosis associated immune reconstitution inflammatory syndrome in patients infected with HIV: meningitis a potentially life-threatening manifestation. AIDS Res. Ther., 2012, vol. 9, is.1, pp. 17. doi: 10.1186/1742-6405-9-17
12. Walker Naomi F., James Scriven, Graeme Meintjes, Robert J. Wilkinson. Immune reconstitution inflammatory syndrome in HIV-infected patients. HIV AIDS, 2015, vol. 7, pp. 49-64. doi: 10.2147/HIV.S42328.
Review
For citations:
Korzh E.V., Podchos N.A. Tuberculous meningitis in patients with concurrent tuberculosis and HIV infection who have started antiretroviral therapy: the specific course and prognosis. Tuberculosis and Lung Diseases. 2019;97(9):5-10. (In Russ.) https://doi.org/10.21292/2075-1230-2019-97-9-5-10
Views:
3246
Email this article 